Bavaria Calls for Complete Reversal of Cannabis Legalization in Germany

As debates continue over the partial legalization of cannabis in Germany, Bavaria has renewed its demand for a full reversal of the policy. The southern German state is urging the federal government to abandon the legalization framework that was introduced in 2024, citing concerns over public health and youth protection.

The legalization of cannabis consumption for personal use, permitted under specific conditions since April 2024, remains a contentious issue. The legislation currently allows adults to possess up to 25 grams of cannabis in public and store up to 50 grams at home. Legal acquisition is possible through self-cultivation--up to three plants per individual--or by joining a cultivation association, from which members can obtain up to 50 grams per month.

Bavaria's health authorities are advocating for stricter prevention and education measures, particularly among young people. The state intends to strengthen existing drug prevention efforts in educational institutions, including vocational schools and universities. Plans are underway to launch new awareness initiatives, such as the 'Mindzone' project, targeting university party environments to inform students about the risks associated with cannabis use. Additionally, a mobile application is in development to provide interactive education on drug dangers for teenagers.

Nationally, the legal status of cannabis remains under review. The current coalition government, comprising Christian Democrats and Social Democrats, has agreed to evaluate the impact of legalization before considering further action. An interim report on the influence of the policy on organized crime related to cannabis is expected by April 2026, with a comprehensive evaluation due in 2028.

Medical professionals and health organizations have expressed concerns over the health risks tied to cannabis consumption. Recent calls from the Federal Union of German Associations of Pharmacists (ABDA) emphasize the need for tighter regulations on cannabis clubs. The ABDA points to research indicating that cannabis use may heighten the risk of cardiovascular fatalities and Type 2 diabetes, as well as interact adversely with various medications, including blood thinners, psychiatric drugs, and specific cancer treatments.

Despite the increased availability of cannabis, data from the past 18 months show little significant change in overall drug consumption patterns. There has been a slight rise in usage among adults, while consumption among teenagers has marginally declined. Nevertheless, health experts warn that the expansion of telemedicine platforms has led to a surge in prescriptions for medical cannabis, raising questions about the legitimacy of many of these prescriptions and the potential for misuse.

Federal officials are pushing for clearer distinctions between recreational and medical cannabis. They argue that medical cannabis should be subject to the same rigorous standards as other pharmaceuticals, and that current possession limits could inadvertently benefit small-scale dealers. The government has signaled its intention to tighten the rules around telemedicine and limit the channels through which cannabis can be legally prescribed and distributed.

As the evaluation process continues, Bavaria remains steadfast in its opposition to the current legal framework, insisting that a comprehensive reversal is necessary to protect public health and prevent increased drug use among young people. The ongoing review by the federal government will play a crucial role in shaping the future of cannabis regulation across Germany.